News Headlines Article

FDA approves prostate cancer ‘vaccine’ from Dendreon called Provenge
Washington Post

The first cancer treatment that harnesses the power of a patient’s immune system to fight tumors won government approval Thursday, a step scientists and patient groups hailed as what could be the beginning of a new era in cancer therapies.

The Food and Drug Administration approved Provenge, sometimes called a “cancer vaccine” because it stimulates the immune systems of men with advanced prostate cancer to attack their malignancies.